ATTO

15.1003.08%
HZ

Hangjun Zhan

Chief Technology Officer

Dr. Hangjun Zhan, Ph. D., was Chief Scientific Officer of Alamar Biosciences, Inc. from January 2022. Dr. Zhan joined the Alamar Biosciences, Inc. in January 2022. He is Chief Technology Officer of Attovia Therapeutics, Inc. He was Chief Scientific Officer of Kindred Biosciences, Inc./Elanco since January 16, 2018. He is Co-Founder of Vetmab Biosciences, Inc. and serves as its Chair of the Scientific Advisory Committee & Director. He served as Senior Vice President of Biologics Research at Kindred Biosciences, Inc. until January 2018. Dr. Zhan served as Director of Protein Sciences at Aragen Bioscience, Inc. Dr. Zhan is experienced in the biotechnology sector and is a world-renowned expert in protein design, expression, production, biochemistry and biophysics. He joined Exelixis Inc. in 2000 to establish the Protein Biochemistry Group. As Senior Director of Exelixis, he successfully managed a team of scientists with diverse technical backgrounds (Molecular Biology, Protein Chemistry, Biophysics, Mass Spec and Chemical Engineering). His team contributed directly to Exelixis' drug discovery programs, leading to more than 10 clinical trials. Prior to joining Exelixis, Dr. Zhan was Group Leader of Protein Chemistry at Axys Biopharmaceuticals (Celera), where he managed a fermentation group and a protein biochemistry group. He worked at Arris. Dr. Zhan is also the lead author of many peer-reviewed publications and book chapters. He is an author on 20+ peer-reviewed articles and 50+ published patents. He holds B. Sc. degree from Zhejiang University, M.S. and Ph.D. degrees from the University of Washington and completed a post-doctoral fellowship at Harvard Medical School.

Positions